Advances in Molecular Diagnostics are aiding physicians in the diagnosis, staging, and treatment of many of today’s most prevalent cancers. The role of molecular diagnostics in the selection of targeted therapies carries with it the hope of optimizing treatment outcomes and has spawned the emergence of companion diagnostics in oncology.
Pharmspective’s Molecular Diagnostics Insights in Oncology: Melanoma evaluates the emerging molecular diagnostics landscape and its role and influence in decisions to use targeted therapies. Pharmspective’s evaluation of this landscape includes:
Perspective on the role and influence of emerging assays in cancer diagnostics in Melanoma (BRAF, c-Kit, S-100, Tumor Mitotic Rate)
Role and influence of molecular diagnostics in treatment staging, monitoring, and selection
Influence of diagnostic test results on treatment authorization for reimbursement
Role and influence of specific cancer diagnostics manufacturers in shaping perception and decision-making involving molecular diagnostics
Perspective on which therapies have been most impacted by the emerging assays
This report will provide immediate value to:
Brand Directors - Insight into opportunities and threats to brand adoption
Medical Marketing Support - Insight into current use of emerging diagnostics
Market Research - Ongoing tracking of key trends
Payer Marketing/Access & Reimbursement - Insights into challenges created by payer reimbursement policies related to molecular diagnostics
Sales Leadership - Regional perspective of the buying process and the opportunities and challenges facing sales personnel
Please note: The Online Download version of the report is for a Single Site License version – one location ONLY.